Literature DB >> 16135192

Control of mucocutaneous leishmaniasis, a neglected disease: results of a control programme in Satipo Province, Peru.

Jean-Paul Guthmann1, Doris Arlt, Luis Miguel Leon Garcia, Milena Rosales, Juan de Jesus Sanchez, Eugenia Alvarez, Sylvaine Lonlas, Mado Conte, Guillermo Bertoletti, Christophe Fournier, Roberto Huari, Els Torreele, Alejandro Llanos-Cuentas.   

Abstract

Mucocutaneous leishmaniasis (MCL) is an important health problem in many rural areas of Latin America, but there are few data on the results of programmatic approaches to control the disease. We report the results of a control programme in San Martin de Pangoa District, which reports one of the highest prevalences of MCL in Peru. For 2 years (2001--2002), the technicians at the health post were trained in patient case management, received medical support and were supplied with antimonials. An evaluation after 2 years showed the following main achievements: better diagnosis of patients, who were confirmed by microscopy in 34% (82/240) of the cases in 2001 and 60% of the cases (153/254) in 2002; improved follow-up during treatment: 237 of 263 (90%) patients who initiated an antimonial therapy ended the full treatment course; improved follow-up after treatment: 143 of 237 (60%) patients who ended their full treatment were correctly monitored during the required period of 6 (cutaneous cases) or 12 (mucosal cases) months after the end of treatment. These achievements were largely due to the human and logistical resources made available, the constant availability of medications and the close collaboration between the Ministry of Health, a national research institute and an international non-governmental organization. At the end of this period, the health authorities decided to register a generic brand of sodium stibogluconate, which is now in use. This should allow the treatment of a significant number of additional patients, while saving money to invest in other facets of the case management.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16135192     DOI: 10.1111/j.1365-3156.2005.01460.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  5 in total

1.  Global Burden of Skin Disease: Inequities and Innovations.

Authors:  Divya Seth; Khatiya Cheldize; Danielle Brown; Esther F Freeman
Journal:  Curr Dermatol Rep       Date:  2017-08-07

2.  Treating cutaneous leishmaniasis patients in Kabul, Afghanistan: cost-effectiveness of an operational program in a complex emergency setting.

Authors:  Richard Reithinger; Paul G Coleman
Journal:  BMC Infect Dis       Date:  2007-01-30       Impact factor: 3.090

3.  Native rodent species are unlikely sources of infection for Leishmania (Viannia) braziliensis along the Transoceanic Highway in Madre de Dios, Peru.

Authors:  Lisa A Shender; Maxy De Los Santos; Joel M Montgomery; Patricia A Conrad; Bruno M Ghersi; Hugo Razuri; Andres G Lescano; Jonna A K Mazet
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

4.  Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.

Authors:  Brandon A Berger; Alexandra Cossio; Nancy Gore Saravia; Maria Del Mar Castro; Sergio Prada; Allison H Bartlett; Mai T Pho
Journal:  PLoS Negl Trop Dis       Date:  2017-04-06

5.  Epidemiological aspects of American cutaneous leishmaniasis (ACL) in an endemic area of forest extractivist culture in western Brazilian Amazonia.

Authors:  Andreia Fernandes Brilhante; Leonardo Augusto Kohatsu Melchior; Vânia Lúcia Brandão Nunes; Cristiane de Oliveira Cardoso; Eunice Aparecida Bianchi Galati
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-13       Impact factor: 1.846

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.